



1FW
1626

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

ATTORNEY DOCKET NO.:
01662/50308

Application Number
09/997,126

Filing Date
November 29, 2001

Examiner
Fiona Powers

Art Unit
1626

Invention Title
Novel Crystal Forms of Atorvastatin Hemi-Calcium
and Processes for their Preparation as Well as Novel
Processes for Preparing Other Forms

Inventor(s)
ARONHIME et al.

Address to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: MAY 25, 2005

Signature: Joseph A. Coppola

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. § 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.
4. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. *1.17(p) (submission of an information disclosure statement under *1.97(c)) fee of **\$180.00** and any additional fees that may be required to the deposit account of Kenyon & Kenyon, deposit account number **11-0600**.
5. A duplicate copy of this communication is enclosed for charging purposes.

Dated: MAY 25, 2005

By:

Joseph A. Coppola
Joseph A. Coppola (Reg. No. 38,413)

CUSTOMER NUMBER 26646

KENYON & KENYON
One Broadway
New York, New York 10004-1050
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 1662/50308	SERIAL NO. 09/997,126
	APPLICANT ARONHIME et al.	
	FILING DATE November 29, 2001	GROUP 1626

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	6,528,661	March 4, 2003	Niddam et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	K.L. Baumann et al., "The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase," Tetrahedron Letters, Vol. 33, No. 17 (1992) pp. 2283-2284
	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. (1996) pp. 879-881

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	